These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


183 related items for PubMed ID: 8490080

  • 1. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
    Brunner G, Arnold R, Hennig U, Fuchs W.
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():51-5, discussion 61-6. PubMed ID: 8490080
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
    Brunner GH, Lamberts R, Creutzfeldt W.
    Digestion; 1990; 47 Suppl 1():64-8; discussion 76. PubMed ID: 2093018
    [Abstract] [Full Text] [Related]

  • 3. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
    Brunner G, Harke U.
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():59-64. PubMed ID: 8180296
    [Abstract] [Full Text] [Related]

  • 4. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
    Brunner G, Creutzfeldt W.
    Scand J Gastroenterol Suppl; 1989; 166():101-5; discussion 111-3. PubMed ID: 2513641
    [Abstract] [Full Text] [Related]

  • 5. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
    Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P.
    Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
    [Abstract] [Full Text] [Related]

  • 6. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
    Brunner G, Creutzfeldt W, Harke U, Lamberts R.
    Digestion; 1988 Aug; 39(2):80-90. PubMed ID: 3410170
    [Abstract] [Full Text] [Related]

  • 7. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M, McFarland M, Sabesin S, Lehman GA, Castell D.
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [Abstract] [Full Text] [Related]

  • 8. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB, Faulds D, McTavish D.
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [Abstract] [Full Text] [Related]

  • 9. Safety profile of Lansoprazole: the US clinical trial experience.
    Freston JW, Rose PA, Heller CA, Haber M, Jennings D.
    Drug Saf; 1999 Feb; 20(2):195-205. PubMed ID: 10082075
    [Abstract] [Full Text] [Related]

  • 10. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
    Arroyo Villarino MT, Lanas Arbeloa A, Esteva Díaz F, Ortego Fernández de Retana J, Sainz Samitier R.
    Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
    [Abstract] [Full Text] [Related]

  • 11. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 12. Effect of lansoprazole on peptic ulcers.
    Ohashi T, Sakata J, Haraguchi Y, Eto T.
    J Clin Gastroenterol; 1995 Sep; 20 Suppl 2():S83-5. PubMed ID: 7594350
    [Abstract] [Full Text] [Related]

  • 13. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ, Jarvis B.
    Drugs; 2001 Sep; 61(12):1801-33. PubMed ID: 11693467
    [Abstract] [Full Text] [Related]

  • 14. Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial.
    Michel P, Lemaire M, Colin R, Bommelaer G, Rambaud JC, Dupas JL, Bigard MA, Verwaerd JC.
    Aliment Pharmacol Ther; 1994 Feb; 8(1):119-22. PubMed ID: 8186337
    [Abstract] [Full Text] [Related]

  • 15. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
    Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM.
    Arch Intern Med; 2000 May 22; 160(10):1455-61. PubMed ID: 10826458
    [Abstract] [Full Text] [Related]

  • 16. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM, Faulds D.
    Drugs; 1994 Sep 22; 48(3):404-30. PubMed ID: 7527761
    [Abstract] [Full Text] [Related]

  • 17. Rapid healing of gastric ulcers with lansoprazole.
    Bardhan KD, Ahlberg J, Hislop WS, Lindholmer C, Long RG, Morgan AG, Sjostedt S, Smith PM, Stig R, Wormsley KG.
    Aliment Pharmacol Ther; 1994 Apr 22; 8(2):215-20. PubMed ID: 8038354
    [Abstract] [Full Text] [Related]

  • 18. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
    Meining A, Kiel G, Stolte M.
    Aliment Pharmacol Ther; 1998 Aug 22; 12(8):735-40. PubMed ID: 9726386
    [Abstract] [Full Text] [Related]

  • 19. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A, Dattilo M.
    Ital J Gastroenterol Hepatol; 1997 Aug 22; 29(4):312-9. PubMed ID: 9476183
    [Abstract] [Full Text] [Related]

  • 20. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
    Londong W, Barth H, Dammann HG, Hengels KJ, Kleinert R, Müller P, Rohde H, Simon B.
    Aliment Pharmacol Ther; 1991 Jun 22; 5(3):245-54. PubMed ID: 1888824
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.